Green Tea (Camellia sinensis)
1. Identity and Botanical Description
Green tea is produced from the leaves and leaf buds of Camellia sinensis (L.) Kuntze, a plant belonging to the family Theaceae. Camellia sinensis is the source of various types of tea, including green tea, black tea, and oolong tea. The tea plant can occur as a shrub or an evergreen tree. Its leaves vary from exstipulate, lanceolate to obovate, up to 30 cm long and 2–5 cm broad, and are serrate, acute, or acuminate.
The critical distinction between green tea and other teas derived from the same plant lies in its processing. Both green tea and black tea are produced from the leaves of Camellia sinensis; however, green tea, unlike black tea, is unfermented, which helps to preserve its antioxidant polyphenolic catechols. To stop the fermentation process that would otherwise reduce the polyphenol content, freshly harvested green tea leaves are steamed immediately upon harvest.
1.1 Common Forms and Preparations
Green tea is available in multiple preparations that differ substantially in their content and bioavailability of active compounds:
- Loose-leaf and bagged tea (infusion): A typical cup of brewed green tea (240 mL) contains 30–60 mg of caffeine, 8–25 mg of L-theanine, and 25–200 mg of catechins. One cup of Camellia sinensis green tea contains approximately 50 mg of EGCG-equivalent, though the amount varies depending on species, length of steeping, and time spent oxidizing.
- Matcha: Matcha is a distinctive form of green tea made by grinding entire shade-grown leaves into a fine powder. The shading process before harvest boosts chlorophyll and L-theanine content, giving matcha its vibrant green color and rich umami taste. Japanese matcha is prepared by adding the fine tea powder to hot water and whisking the mixture together to create a slightly frothy drink. The powdering process with a ceramic mill and stirring in hot water has been shown to increase the average extracted concentration of EGCG by more than three times compared with leaf tea.
- Green tea extract (GTE): Green tea extract (GTE) is a dietary supplement derived from Camellia sinensis leaves. GTE contains a large number of concentrated components, including non-oxidized polyphenols, vitamins, and antioxidants. Green tea supplements, including green tea extract, catechins, and L-theanine, are available in the forms of pills, capsules, liquid, and powder.
Processing methods also differ regionally. Japanese green teas are steamed immediately after harvest to halt oxidation, preserving bright green color and fresh, grassy flavors, while Chinese green teas are typically pan-fired (dry-roasted), which produces a more toasted, mellow character.
2. Traditional and Historical Use
2.1 Origins in China
Tea originated in southwest China roughly 5,000 years ago, making it one of the oldest consumed beverages in human history. The earliest credible evidence of tea consumption dates to the Shang Dynasty (1500–1046 BCE) in China's Yunnan province, where wild tea trees still grow today. Tea in China has existed for over 3,000 years, with the first notes on tea history dating back to the 8th century, when steaming the leaves to halt oxidation was discovered.
By the Tang Dynasty (AD 618–907), tea drinking had become a well-established part of Chinese society and culture. The Tang Dynasty is widely referred to as the Golden Age of tea culture. Scholars compiled preparation methods, farming techniques, and ceremonial etiquette associated with tea culture. A key publication on the topic was Lu Yu's Classic of Tea, which helped to organize the body of knowledge surrounding tea use and elevated the art of drinking tea to high esteem.
The process of picking young and tender green tea leaves in spring, then roasting and baking them into whole separate tea leaves, existed during the Tang and Song dynasties, but it was not until the Ming (1368–1644) and Qing (1644–1912) dynasties that whole-leaf tea became the predominant way to drink tea in China.
2.2 Introduction to Japan
During the Nara and Heian periods, Buddhist monks travelling to China brought back tea seeds and plants, introducing green tea to Japan, where it was initially consumed in Buddhist temples for its health benefits and as an aid to meditation. The monks found that tea helped them stay calm and alert during long periods of meditation.
As the 12th century approached, Monk Eisai helped promote tea for health and clarity of mind. Eisai's book Kissa Yojoki played a major role in spreading tea culture in Japan. By the 15th century, the ceremonial preparation and consumption of tea had become a central part of Japanese culture, embodying Zen principles such as mindfulness and simplicity. It was during this time that the tea ceremony, or chanoyu, took its formal shape.
From the late 15th century to the late 16th century, tea masters such as Murata Shuko, Takeno Joo, and Sen no Rikyu developed a new tea ceremony referred to as Wabicha, which gained a strong following among the Samurai class and is the origin of the tea ceremony practiced today. In Kyoto, Soen Nagatani of Ujitawarakyo developed a high-quality Sencha in 1738, said to be the forebear of modern Sencha.
2.3 Traditional Medicinal Uses
Green tea has long been considered medicine throughout India, China, Japan, and Thailand. Historically, it was used across Asian traditions as a stimulant to promote alertness, as a digestive aid, and as a general restorative tonic. Green tea has long been believed to have health-restoring properties and its ingredients to have antioxidant activity; extracts of green tea have historically been used as herbal medication purported to improve health, prevent cancer and heart disease, decrease serum lipid levels, promote weight loss, and decrease periodontal disease.
3. Key Constituents and Active Compounds
3.1 Polyphenols and Catechins
Green tea contains an array of components, including xanthine derivatives (caffeine, theophylline, and theobromine), the glutamine derivative theanine, and phenolic compounds known as catechins: catechin, epicatechin, epicatechin-3-gallate, epigallocatechin, and epigallocatechin-3-gallate (EGCG). Catechins make up 95% of green tea's phenolic content.
The major phenolic compounds found in green tea are flavonoids, accounting for nearly 70% of its total polyphenols. Green tea is rich in polyphenol flavonoids including catechins; epigallocatechin-3-gallate (EGCG) is the most abundant and potent green tea catechin, and has been extensively studied for its beneficial health effects as a nutraceutical agent.
3.2 Amino Acids: L-Theanine
Green tea contains several substances that affect cognitive function, including caffeine, L-theanine, and catechins. L-theanine is an amino acid found almost exclusively in the tea plant. The combination of caffeine and L-theanine is almost unique to the tea plant. L-theanine modulates serotoninergic, dopaminergic, and GABAergic neurotransmission in the brain.
3.3 Alkaloids
Green tea contains the purine alkaloids caffeine, theophylline, and theobromine. These xanthine-class compounds contribute to the mild stimulant effect of the beverage and also interact synergistically with catechins in some of green tea's pharmacological properties.
3.4 Additional Constituents
Green tea also contains triterpenoid saponins, minerals, and trace elements, alongside its polyphenol and alkaloid fractions. Tea contains around 4,000 bioactive compounds represented by polyphenols (mostly flavonoids) and alkaloids (caffeine, theophylline, and theobromine).
4. Mechanisms of Action
4.1 Antioxidant and Free Radical Scavenging
EGCG, with its polyphenolic structure, is well recognized as a strong antioxidant through its activities in quenching reactive radicals and chelating metal ions to prevent the formation of reactive oxygen species (ROS). An antioxidant (catechin-enriched) fraction of Chinese green tea was shown to be active in directly detoxifying hydrogen peroxide and superoxide radicals and thus protected cultured mouse hepatocytes and human keratinocytes in vitro.
The bulk of evidence has shown that the cardioprotective activity of green tea is mainly attributed to the antioxidant properties of its catechins, which act by inducing antioxidant enzymes, inhibiting pro-oxidant enzymes, and scavenging free radicals.
4.2 EGCG: Pro-oxidant Effects and Indirect Antioxidant Activity
EGCG's mechanism is not limited to simple antioxidant action. Treatment of cells with EGCG results in production of hydrogen peroxide and hydroxyl radicals in the presence of Fe(III), meaning EGCG functions as a pro-oxidant in some cellular contexts. Recent investigations have revealed many direct actions of EGCG that are independent from anti-oxidative mechanisms. At moderate levels, the ROS produced can be beneficial via induction of Nrf2-mediated antioxidant and cytoprotective enzymes, generally referred to as the indirect antioxidant activity of EGCG. These enzymes play far more important roles in cytoprotection than the direct free radical scavenging activity of EGCG.
4.3 Signal Transduction and Gene Regulation
EGCG directly interacts with proteins and phospholipids in the plasma membrane and regulates signal transduction pathways, transcription factors, DNA methylation, mitochondrial function, and autophagy to exert many of its biological actions.
Tea polyphenols are known to inhibit metalloproteinases, various protein kinases, and proteins that regulate DNA replication and transformation. EGCG potently and specifically inhibited tumor proteasomal activity in vitro.
4.4 Anti-inflammatory Mechanisms
EGCG suppresses inflammation in human coronary artery endothelial cells by inhibiting NF-κB, inhibits enhanced expression of adhesion molecules such as VCAM-1 and ICAM-1, and attenuates monocyte adhesion. The antioxidant effects of EGCG may be at least partially mediated by upregulating Nrf2/HO-1 via activation of p38 MAPK and ERK1/2 signaling pathways.
4.5 Anti-tumor Mechanisms
The mechanisms by which tea polyphenols may act against tumor development include inhibition of mutagenesis, genotoxicity, transformation, cell proliferation, and angiogenesis. EGCG enhances gap junctional communication between adjacent cells and thus protects cells from tumor development, as tumor promoters inhibit gap junctional intercellular communication and isolate preneoplastic cells from the regulatory influence of surrounding cells.
4.6 Cholesterol and Lipid Metabolism
The exact mechanism by which green tea reduces cholesterol is not fully understood, but proposed mechanisms include an increase in thermogenesis, enhanced gene expression of enzymes involved in bile acid production, and appetite suppression.
4.7 Neuroprotective Mechanisms
Green tea may exert neuroprotective effects through multiple mechanisms, including: tea polyphenols inhibiting acetylcholinesterase (a target for Alzheimer's disease medications); green tea extract regulating the secretion of stress hormones such as corticosterone; and L-theanine modulating serotoninergic, dopaminergic, and GABAergic neurotransmission in the brain. Green tea and its polyphenols have numerous potential neuroprotective effects, including antioxidant and iron-chelating activity, anti-inflammatory actions (by reducing pro-inflammatory cytokines, microglial activation, and the TLR4/NF-κB pathway), and anti-amyloid/tau effects by inhibiting aggregation.
5. Scientific Evidence by Area of Use
5.1 Cancer Prevention
Cancer prevention is one of the most extensively studied areas for green tea, yet also one of the most inconclusive.
Although tea and/or tea polyphenols have been found in animal studies to inhibit the growth of tumors in different parts of the body, the results of human studies — both epidemiologic and clinical — have been inconclusive.
Green tea (Camellia sinensis) is rich in catechins, of which EGCG is the most abundant. Studies in animal models of carcinogenesis have shown that green tea and EGCG can inhibit tumorigenesis during the initiation, promotion, and progression stages. Many potential mechanisms have been proposed, including both antioxidant and pro-oxidant effects, but questions remain regarding the relevance of these mechanisms to cancer prevention in humans.
At the level of human epidemiology, for certain individual cancer sites — endometrial, lung, oral, and ovarian cancer, and non-Hodgkin's lymphoma — the majority of meta-analyses observed an inverse association with green tea. Mixed findings were observed for breast, esophageal, gastric, and liver cancer, and a mostly null association was found for colorectal, pancreatic, and prostate cancer.
Although the overall clinical evidence is inconclusive, habitual green tea consumption may provide some level of chemoprevention in prostate and breast cancer. Although many studies have been done on green tea and its extracts, definite conclusions cannot yet be reached on whether green tea is helpful for most of the purposes for which it is used.
A notable regulatory development concerns the use of topical preparations: Veregen, a green tea polyphenol ornament preparation with EGCG as the major constituent, has been approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) as a drug for topical treatment of external genital and anal warts caused by papillomavirus. The FDA has approved a specific green tea extract ointment as a prescription drug for treating genital warts.
Evidence strength: Predominantly preliminary (in vitro, animal, and observational epidemiology). Interventional human evidence is insufficient to establish green tea as an effective cancer preventive agent for most cancer types. The topical Veregen preparation represents a specific regulatory exception supported by clinical trial data for HPV-associated warts.
5.2 Cardiovascular Health
The literature overall supports an inverse association between green tea and cardiovascular disease-related health outcomes. Observational studies have suggested a primary preventive role of green tea against cardiovascular diseases such as stroke, coronary heart disease, and coronary atherosclerosis. Results from a large cohort study showed that daily consumption of 2 cups of green tea was associated with a 22–33% reduction in CVD-caused mortality among a Japanese population.
In terms of clinical trial data, among 11,286 studies identified in a systematic review, 55 eligible RCTs with 63 effect sizes were included. Results from the random effects meta-analysis showed that green tea extract (GTE) supplementation significantly reduced total cholesterol (WMD = −7.62 mg/dL), LDL-C (WMD = −5.80 mg/dL), fasting blood sugar (WMD = −1.67 mg/dL), HbA1c (WMD = −0.15%), and diastolic blood pressure (WMD = −0.87 mmHg), while increasing HDL-C (WMD = +1.85 mg/dL).
With respect to cholesterol specifically, green tea reduced total cholesterol and LDL cholesterol to a small extent, but it did not affect HDL cholesterol or triglycerides, according to the NCCIH. Very few long-term studies have looked at the effects of tea on heart disease risk; however, the limited evidence currently available suggests that both green and black tea might have beneficial effects on some heart disease risk factors, including blood pressure and cholesterol.
In a double-blind randomized controlled trial of 30 obese subjects, EGCG treatment (150 mg twice daily, orally) for 8 weeks significantly decreased systolic blood pressure, diastolic blood pressure, and mean arterial pressure.
Evidence strength: Moderate. Observational evidence from large Asian cohorts is consistent. RCT meta-analyses demonstrate statistically significant but numerically modest reductions in LDL and total cholesterol. High inter-study heterogeneity limits certainty. Long-term cardiovascular endpoint data (e.g., myocardial infarction rates) from randomized trials are lacking.
5.3 Body Weight and Obesity
Today, green tea and its extracts are promoted as dietary supplements for, among other things, losing weight and reducing blood cholesterol levels. Green tea has not been shown to be effective for weight loss, according to the NCCIH's summary of available evidence.
However, a meta-analysis of RCTs provides more nuanced findings. Thirty-eight studies reported body mass as an outcome measure, and overall results from the random effects model indicated that GTE supplementation resulted in a significant reduction in body mass (WMD: −0.64 kg; 95% CI: −0.97, −0.30; P < 0.001).
One randomized, double-blind, placebo-controlled clinical trial found that 12 weeks of treatment with high-dose green tea extract (856.8 mg EGCG daily) resulted in significant weight loss, reduced waist circumference, and a decrease in total cholesterol and LDL plasma levels in women with central obesity. The anti-obesity mechanism of high-dose green tea extract was proposed to be associated in part with ghrelin secretion inhibition, leading to increased adiponectin levels.
The benefits of green tea catechins on lipid oxidation and related fat-burning pathways appear to be achieved in a dose-dependent manner, with significant effects noted only at high doses, such as 400 to 500 mg of EGCG equivalent per day.
Evidence strength: Low to moderate. While statistically significant weight reductions have been reported in RCTs, the absolute magnitude is small (less than 1 kg on average in meta-analyses). The NCCIH characterizes the overall evidence as insufficient to establish effectiveness. Effects appear dose-dependent and are most pronounced at higher EGCG doses that may carry safety concerns.
5.4 Type 2 Diabetes and Glycemic Control
The evidence for diabetes-related health outcomes is less convincing, while meta-analyses generally suggested an inverse association between green tea and BMI-related and blood pressure outcomes.
In a randomized, double-blind, placebo-controlled trial conducted at Taipei City Hospital, 102 patients with type 2 diabetes were enrolled and subjects were randomly allocated to receive decaffeinated GTE EGCG or a placebo (cellulose) for 16 weeks; capsules contained 500 mg of decaffeinated GTE extract. The trial examined effects on insulin resistance and glucagon-like peptide 1 (GLP-1) among participants with lipid abnormalities.
A broader meta-analysis reported that GTE supplementation significantly reduced fasting blood sugar (WMD = −1.67 mg/dL; 95% CI: −2.58, −0.75; P < 0.001) and HbA1c (WMD = −0.15%; 95% CI: −0.26, −0.04; P = 0.008) across 55 eligible RCTs.
Evidence strength: Low to moderate. Meta-analytic findings show statistically significant but numerically small effects on glycemic markers. Individual RCTs have been conducted in specific populations (e.g., existing type 2 diabetes, obesity, lipid abnormalities), and results may not generalize broadly. The NCCIH characterizes diabetes-related evidence as less convincing than that for cardiovascular outcomes.
5.5 Neurological Health and Cognitive Function
Many population-based cohort investigations have demonstrated that drinking tea is related to a lower risk of cognitive impairment. A follow-up study for 5.7 years involving 13,645 Japanese people over 65 years old showed that green tea consumption significantly reduced the risk of dementia. A study among 278 Parkinson's disease patients revealed that the onset of PD was delayed by 7.7 years when tea consumption was more than 3 cups per day.
In a clinical trial, decreasing oxidative markers including malondialdehyde and 8-OGdG, and an increase in MMSE score and total antioxidant capacity of plasma were significantly documented by green tea consumption, suggesting a protective effect on cognitive function relevant to Alzheimer's disease.
A pilot study in vascular dementia patients found that post hoc analysis of vascular dementia data (n = 8) showed that total MMSE-J scores and short-term memory domain scores were significantly improved after three months of green tea consumption, indicating potential as a neuroprotective agent especially for vascular dementia. The main limitation was the non-blinded, non-placebo controlled design.
For Down syndrome, some positive effects of EGCG on cognitive function have been observed in people with Down syndrome. In a pilot study of 29 patients with Down syndrome, EGCG (9 mg/day) for 3 months significantly improved episodic memory.
Evidence from clinical trials is less consistent, possibly due to variations in the forms of green tea/extract tested, the duration of the studies, and the cognitive outcomes tested. Overall, reviews clarify that green tea has potent neuroprotective effects especially in vitro and in vivo (animal models); however, further genomic, molecular, and clinical trials are needed to understand the range and mechanism of action of green tea in humans.
Evidence strength: Preliminary to low. Epidemiological associations are encouraging. Several small clinical trials show positive signals in specific populations (vascular dementia, Down syndrome), but the trials are methodologically limited (small samples, short duration, lack of blinding). No definitive human evidence establishes green tea as an effective treatment or prevention for Alzheimer's disease or Parkinson's disease.
5.6 Oral Health
Numerous studies have suggested beneficial effects of green tea on oral conditions such as dental caries, periodontal diseases, and halitosis. It has been reported that green tea protects against bacterial-induced dental caries. Green tea extract has been shown to inhibit the onset of periodontal destruction (loss of attachment and alveolar bone resorption) in experimental periodontitis in rats.
However, more clinical data are required to ascertain the possible benefits of green tea consumption on oral health.
Evidence strength: Preliminary. Evidence is primarily from in vitro and animal studies. Limited clinical human trial data are available, and the evidence base is insufficient for firm clinical conclusions.
5.7 Antiviral Activity (HPV/Genital Warts)
This is the most clinically established application of a specific green tea-derived preparation. The U.S. Food and Drug Administration (FDA) has approved a topical ointment containing a specific green tea extract for the treatment of external genital and perianal warts. The approved product, Veregen (sinecatechins 15% ointment), is the principal example of a green tea-derived pharmaceutical used in regulated clinical practice, and its approval was based on controlled clinical trials.
6. Body Systems and Health Areas Associated with Green Tea
- Cardiovascular system: Lipid modulation (LDL, total cholesterol), blood pressure, endothelial function, and antioxidant protection of vascular tissue.
- Metabolic system: Glycemic control (fasting blood glucose, HbA1c), insulin sensitivity, and body weight modulation.
- Oncological (cancer biology): Antiproliferative, pro-apoptotic, and anti-angiogenic activity in tumor models; epidemiological inverse associations with certain cancer types.
- Nervous system: Neuroprotection via antioxidant, anti-amyloid, anti-tau, and anti-inflammatory pathways; cognitive function modulation through L-theanine and caffeine.
- Oral/dental: Antibacterial effects relevant to dental caries and periodontal disease.
- Dermatological/integumentary: Topical anti-inflammatory and antiviral use (FDA-approved Veregen for HPV-related genital warts).
- Immunological: Anti-inflammatory mechanisms via NF-κB suppression and Nrf2 pathway activation.
7. Dosage Forms and Dosages Reported in Studies
Clinical trials examining the effects of EGCG on cognitive function, cholesterol levels, blood pressure, and insulin resistance have used doses ranging from 9 to 1,200 mg per day, with many studies using 300 mg or more.
- Infused beverage: A typical cup of brewed green tea (240 mL) contains 30–60 mg of caffeine, 8–25 mg of L-theanine, and 25–200 mg of catechins.
- Cardiovascular RCTs: A 2022 meta-analysis of 55 RCTs examined doses above and below 1,000 mg/d of GTE; subgroup analyses demonstrated different results for lipid and glycemic risk factors depending on the duration (≥12 weeks vs. <12 weeks) and dose of GTE (≥1,000 mg/d vs. <1,000 mg/d).
- Blood pressure RCT: EGCG at 150 mg twice daily (orally) for 8 weeks in a double-blind RCT of 30 obese subjects.
- Weight loss RCT: A daily dosage of 856.8 mg EGCG was used in a 12-week randomized, double-blind, placebo-controlled trial in women with central obesity.
- Type 2 diabetes RCT: Subjects received capsules containing 500 mg of decaffeinated GTE extract for 16 weeks.
- Down syndrome pilot study: EGCG at 9 mg/day for 3 months was used in a pilot study of 29 patients with Down syndrome.
- Hepatic safety threshold (observed in reviews): Daily intake of 1,315 mg of green tea catechins containing 843 mg EGCG poses mainly mild, transient hepatic adverse effects.
Most supplement doses are standardized against EGCG content.
8. Safety Considerations and Drug Interactions
8.1 General Safety of Beverage vs. Extract
Green tea, an ancient drink, has a good safety profile when consumed as a beverage but may pose a risk for liver injury when consumed in extract form. Green tea extract might reduce oxidative stress biomarkers and cardiovascular disease risk factors and improve cognitive function; however, the quality of evidence is low to moderate, and high doses can cause liver damage.
8.2 Gastrointestinal Side Effects
Side effects of green tea extract supplements include nausea, constipation, abdominal discomfort, and increased blood pressure.
8.3 Hepatotoxicity
Although uncommon, liver injury has been reported in some people who used green tea products, primarily green tea extracts in tablet or capsule form. Green tea extract and, more rarely, ingestion of large amounts of green tea have been implicated in cases of clinically apparent acute liver injury, including instances of acute liver failure and either need for urgent liver transplantation or death.
The primary component implicated in hepatotoxicity is EGCG, especially with prolonged use, fasting intake, and doses exceeding 800 mg. The use of organic solvents in extraction, such as methanol or chloroform, adds another layer of risk.
The European Food Safety Authority (EFSA) initiated a systematic review on the safety of catechins in 2018. This systematic review identified transaminase and cholestasis parameter increases with daily intake of at least 800 mg EGCG in 9 of 38 intervention studies. Although traditional green tea infusion was considered harmless, a possible causal relationship for liver damage was identified for food supplements with cumulative EGCG doses greater than 800 mg/day.
On the basis of a review in which more than 200 cases involving green tea products were examined by the US Pharmacopeia (USP) Dietary Supplement Information Expert Committee, 27 reports of liver damage were considered possibly or likely caused by GTE-induced toxicity.
Individuals with a specific variant of a gene that plays an important role in immune function appear to be especially susceptible to green tea-induced liver injury, and between 5 and 15 percent of Americans have this variant. Research has identified the HLA-B*35:01 allele as a genetic susceptibility marker. Patients with this allele have been documented in case reports of green tea hepatotoxicity.
Research suggests that people should not go on a calorie-restricted diet while consuming EGCG for weight loss, as the combination significantly increases the risk of liver injury.
8.4 Drug Interactions
Green tea at high doses has been shown to reduce blood levels and therefore the effectiveness of nadolol, a beta-blocker used for high blood pressure and heart problems.
Green tea extract can reduce blood levels of the cholesterol-lowering drug atorvastatin.
The polyphenolic catechins comprise the chemically active component of green tea extract (GTE). The polyphenolic backbone of the catechins is exploited for its antioxidant potential but is likely also responsible for liver injury — a dual nature that complicates the risk-benefit profile of high-dose supplementation.
8.5 Caffeine-Related Considerations
As green tea contains caffeine (in both the beverage and most non-decaffeinated extracts), the standard considerations for caffeine apply, including potential effects on heart rate, blood pressure, sleep quality, and caffeine sensitivity. The interaction between caffeine and L-theanine is characteristic of green tea; the stress-reducing effect of theanine is strongly suppressed by the presence of caffeine and EGCG. Decaffeinated preparations are available specifically to mitigate caffeine-related effects while retaining polyphenol content.
References
- PMC6826564 — A Comprehensive Insight on the Health Benefits and Phytoconstituents of Camellia sinensis
- PMC9231383 — Green Tea (Camellia sinensis): A Review of Its Phytochemistry, Pharmacology, and Toxicology
- PMC4911733 — Green Tea (Camellia sinensis): Chemistry and Oral Health
- PMC3769684 — Molecular Mechanisms of Green Tea Polyphenols
- PMC9820274 — Therapeutic Effects of EGCG in Relation to Molecular Pathways Controlling Inflammation, Oxidative Stress, and Apoptosis
- PMC2946098 — The Antioxidant and Pro-oxidant Activities of Green Tea Polyphenols: A Role in Cancer Prevention
- PubMed 24494192 — New Insights into the Mechanisms of Polyphenols Beyond Antioxidant Properties: Lessons from EGCG
- NCCIH — Green Tea: Usefulness and Safety
- NCCIH — Tea
- NIH LiverTox — Green Tea
- PMC9871939 — The Effects of Green Tea Supplementation on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis
- PubMed 32820240 — Green Tea and Cancer and Cardiometabolic Diseases: A Review of the Current Epidemiological Evidence
- PMC3948786 — Effects of Green Tea Extract on Insulin Resistance and GLP-1 in Patients with Type 2 Diabetes: A Randomized, Double-Blinded, Placebo-Controlled Trial
- PMC4210905 — Green Tea Consumption Affects Cognitive Dysfunction in the Elderly: A Pilot Study
- PMC8033961 — Green Tea, A Medicinal Food with Promising Neurological Benefits
- PMC8401650 — Green Tea Suppresses Brain Aging
- PMC6017384 — Neuroprotective Effects and Mechanisms of Tea Bioactive Components in Neurodegenerative Diseases
- PMC9745259 — Green Tea Extract–Associated Acute Liver Injury: Case Report and Review
- PMC3746392 — Green Tea Extract: A Potential Cause of Acute Liver Failure
- PMC7878556 — Epigallocatechin Gallate During Dietary Restriction — Potential Mechanisms of Enhanced Liver Injury
- PMC8146271 — Potential Protective Mechanisms of Green Tea Polyphenol EGCG Against COVID-19
- PubMed 17584048 — Green Tea Polyphenols as an Anti-oxidant and Anti-inflammatory Agent for Cardiovascular Protection
- Alzheimer's Drug Discovery Foundation — EGCG Cognitive Vitality For Researchers
- Alzheimer's Drug Discovery Foundation — Green Tea Cognitive Vitality For Researchers
- Examine.com — Green Tea Extract: Benefits, Dosage, and Side Effects
- World History Encyclopedia — The History of Japanese Green Tea
- ITO EN Global — History of Japanese Green Tea
- PMC9936988 — AASLD Practice Guidance on Drug, Herbal, and Dietary Supplement–Induced Liver Injury
- PMC6273883 — The Powdering Process with a Set of Ceramic Mills for Green Tea Promoted Catechin Extraction and the ROS Inhibition Effect
- PMC8080935 — Effects of L-Theanine on Cognitive Function in Middle-Aged and Older Subjects: A Randomized Placebo-Controlled Study
- PMC11191983 — A Comprehensive Update in Herbal and Dietary Supplement–Induced Liver Injury
Volver